

28 January 2026

[submitted electronically via: HouseHealthandHumanServices@rilegislature.gov]

The Honorable Susan Donovan Chair, House Committee on Health & Human Services
State House

82 Smith Street

Providence, RI 02903

RE: H7075 – AN ACT RELATING TO INSURANCE -- ACCIDENT AND SICKNESS
INSURANCE POLICIES

Dear Chair Donovan and members of the Committee:

I am writing in strong support of **House Bill 7075, the Matt Federico Diabetic Safety Act – Glucagon**. As the Care New England Director of Ambulatory & Value-Based Pharmacy Practice, I lead strategic initiatives to optimize medication management and improve patient outcomes across outpatient settings. I hold a Bachelor of Science in Pharmacy from the University of Rhode Island and a Master of Business Administration from Nichols College. I am also Board Certified in Geriatric Pharmacy (BCGP), a Certified Diabetes Care and Education Specialist (CDCES), and a Fellow of the American Society of Consultant Pharmacists (FASCP). In addition to my leadership role, I serve as Secretary of the Rhode Island Department of Health's Board of Pharmacy, currently in my second term, where I help advance regulatory standards and promote safe, effective pharmacy practice statewide.

House Bill 7075 represents a crucial step toward improving diabetes care and advancing health equity in Rhode Island. The bill eliminates significant cost barriers by requiring insurers to provide **two glucagon devices per year at no cost**, ensuring that life-saving emergency treatment is accessible to all individuals regardless of income or insurance limitations. Furthermore, the legislation mandates coverage of **at least one device from each route of administration**, including auto-injectors, nasal sprays, and other ready-to-use formulations—a vital requirement given that different glucagon products are approved for different age groups and clinical needs. By ensuring access

to modern, easy-to-use options across ages and socioeconomic groups, this bill directly strengthens patient safety and promotes more equitable diabetes care statewide.

For these reasons, I respectfully urge support for House Bill 7075. Ensuring equitable access to emergency glucagon will save lives, prevent avoidable hospitalizations, and improve the overall quality of care for Rhode Islanders living with diabetes.

Thank you for your consideration.

Sincerely,
Stacey Ranucci

Warwick, RI
Director, Ambulatory & Value-Based Pharmacy Practice
Care New England Health System

Stacey J. Ranucci (she/her/hers)

Director of Ambulatory & Value Based Pharmacy Practice
Adjunct Clinical Professor of Pharmacy Practice, URI
Care New England–Integra
M: 401.439.1983 | Sranucci@CareNE.org

